

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  64D0724937	<b>(X3) Date Survey Completed</b>  08/12/2024
<b>Name of Provider or Supplier</b>  Lbj Tropical Medical Center	<b>Street Address, City, State</b>  1234 Paul Turner Dr, Pago Pago, AS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D0000</b>	The following deficiencies are a result of a desk review of proficiency testing scores obtained from the national database and verified with the proficiency testing company. The facility was found to be out of compliance with the conditions of the CLIA program. The following CONDITION LEVEL DEFICIENCIES were found to be out of compliance: D2016 - 42 C.F.R. 493.803 Condition: Successful participation [proficiency testing] D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity. testing; laboratory director
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a proficiency testing desk review of the Certification and Survey Provider</p>

Enhanced Reporting (CASPER) 0155 report and College of American Pathologists (CAP) records, the laboratory failed to successfully participate in a proficiency testing program approved by HHS, for each specialty, subspecialty, and analyte in which the laboratory is certified under CLIA. The laboratory failed to successfully participate in the subspecialty of Routine Chemistry for the Aspartate transaminase (AST) analyte, in the overall subspecialty of Toxicology and for the individual toxicology analytes carbamazepine, lithium, phenobarbital, and theophylline. Refer to D2096, D2118, and D2119

**D2096**

**ROUTINE CHEMISTRY**  
CFR(s): 493.841(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a proficiency testing desk review of the CASPER 0155 report and College of American Pathologists (CAP) 2024 proficiency testing records, the laboratory failed to achieve satisfactory performance (80% or greater) for the same analyte in two of two consecutive testing events (2024 Events 1 and 2) in the subspecialty of Routine Chemistry for the Aspartate Transaminase (AST) analyte. Findings included: 1. Review of the CASPER 0155 report revealed the following results: CAP Chemistry 2024 - 1st Event The laboratory received an unsatisfactory score of 40% for the AST. CAP Chemistry 2024 - 2nd Event The laboratory received an unsatisfactory score of 20% for the AST. 2. A review of CAP 2024 proficiency testing records confirmed the laboratory received the above results.

**D2118**

**TOXICOLOGY**  
CFR(s): 493.845(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a proficiency testing desk review of the CASPER 0155 report and College of American Pathologists (CAP) 2024 proficiency testing records, the laboratory failed to achieve satisfactory performance (80% or greater) for the same analyte in two of two consecutive testing events (2024 Events 1 and 2) in the subspecialty of Toxicology for the individual toxicology analytes carbamazepine, lithium, phenobarbital, and theophylline. 1. Review of the CASPER 0155 report revealed the following results: CAP Chemistry 2024 - 1st Event The laboratory received an unsatisfactory score of 0% for the Carbamazepine. The laboratory received an unsatisfactory score of 0% for the Lithium. The laboratory received an unsatisfactory score of 0% for the Phenobarbital. The laboratory received an unsatisfactory score of 0% for the Theophylline. CAP Chemistry 2024 - 2nd Event The laboratory received an unsatisfactory score of 0% for the Carbamazepine. The laboratory received an unsatisfactory score of 0% for the Lithium. The laboratory received an unsatisfactory

	<p>score of 0% for the Phenobarbital. The laboratory received an unsatisfactory score of 0% for the Theophylline 2. A review of CAP 2024 proficiency testing records confirmed the laboratory received the above results.</p>
<p><b>D2119</b></p>	<p><b>TOXICOLOGY</b> CFR(s): 493.845(g)</p> <p>Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a proficiency testing desk review of the College of American Pathologists (CAP) 2024 proficiency testing records, the laboratory failed to achieve satisfactory performance (80% or greater) for the overall subspecialty of Toxicology in two of two consecutive testing events (2024 Events 1 and 2). A review of CAP 2024 proficiency testing records revealed the following results: 1. CAP Chemistry 2024 - 1st Event The laboratory received an overall unsatisfactory score of 43% for Toxicology. 2. CAP Chemistry 2024 - 2nd Event The laboratory received an overall unsatisfactory score of 43% for Toxicology.</p>
<p><b>D6000</b></p>	<p><b>MODERATE COMPLEXITY LABORATORY DIRECTOR</b> CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.</p> <p>This CONDITION is not met as evidenced by: Based on a proficiency testing desk review of the CASPER 0155 report and College of American Pathologists (CAP) 2024 proficiency testing records, the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016.</p>
<p><b>D6016</b></p>	<p><b>LABORATORY DIRECTOR RESPONSIBILITIES</b> CFR(s): 493.1407(e)(4)(i)</p> <p>The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part;</p> <p>This STANDARD is not met as evidenced by: Based on a proficiency testing desk review of the CASPER 0155 report and College of American Pathologists (CAP) 2024 proficiency testing records, the laboratory director failed to ensure the overall quality of the laboratory services provided. The laboratory director failed to ensure successful participation in an HHS approved proficiency testing program. Refer to D2096, D2118, and D2119.</p>